ICVX实时信号 | 通过Getagraph.com最大化利润

购买 108777 min ago

@ $15.42

发出时间: 14 Feb 2024 @ 04:51

回报率: -0.71%

上一信号: Feb 14 - 02:32

上一信号: 出售

回报率: -0.39 %

Live Chart Being Loaded With Signals

Commentary (17 Feb 2024 @ 05:00):

Stats
今日成交量	8.56M
平均成交量	1.05M
市值	769.04M
EPS	$0 ( 2024-04-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.96
ATR14	$0.208 (1.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-19	Ra Capital Management, L.p.	Sell	638 668	Common Stock
2024-02-19	Ra Capital Management, L.p.	Sell	22 278	Stock Option (Right to Buy)
2024-02-19	Ra Capital Management, L.p.	Sell	17 000	Stock Option (Right to Buy)
2024-02-19	Simpson Adam K.	Sell	129 032	Common Stock
2024-02-19	Simpson Adam K.	Sell	191 449	Stock Option (Right to Buy)

INSIDER POWER
-94.09
Last 100 transactions
Buy: 419 662 \| Sell: 10 978 493

音量相关性

長: 0.31 (neutral)

短: 0.00 (neutral)

Signal:(55.408) Neutral

Icosavax, Inc. 相关性

10 最正相关
TOUR	0.936
TELA	0.931
MOMO	0.927
REPL	0.927
QTT	0.925
FGEN	0.924
VBNK	0.922
GGAL	0.922
FCBP	0.921
NIU	0.919

10 最负相关
THTX	-0.904
GOSS	-0.899
PCRX	-0.895
USCB	-0.894
LARK	-0.891
ENPH	-0.878
SHSP	-0.877
SWAV	-0.875
XFOR	-0.87
NETE	-0.87

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Icosavax, Inc. 相关性 - 货币/商品

-0.48
( neutral )

0.40
( neutral )

0.46
( neutral )

-0.18
( neutral )

0.37
( neutral )

0.54
( weak )

Icosavax, Inc. 财务报表

Annual	2022
营收:	$582 000
毛利润:	$-1.26M (-216.67 %)
EPS:	$-2.23

FY	2022
营收:	$582 000
毛利润:	$-1.26M (-216.67 %)
EPS:	$-2.23

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$0

FY	2020
营收:	$1.62M
毛利润:	$0.00 (0.00 %)
EPS:	$-1.820

Financial Reports:

No articles found.

Icosavax, Inc.

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.